In vitro studies of 223Ra- and 225Ac-labelled α-zirconium phosphate as potential carrier for alpha targeted therapy

Abstract In this study suitability of α-ZrP nanoparticles as a 223 Ra and 225 Ac carriers for TAT was investigated. The yields radiolabelling were higher than 98% in both cases. Subsequently, vitro stability studies carried out various biological matrices during 48 h period. Measurements released radioactivity showed the highest saline. Released activity Ra, their daughter radionuclides around 0.5%. On other hand, lowest shown plasma serum. progeny atoms from 15 to 32%.